LU87007A1 - Compositions pharmaceutiques a base d'urokinase - Google Patents
Compositions pharmaceutiques a base d'urokinase Download PDFInfo
- Publication number
- LU87007A1 LU87007A1 LU87007A LU87007A LU87007A1 LU 87007 A1 LU87007 A1 LU 87007A1 LU 87007 A LU87007 A LU 87007A LU 87007 A LU87007 A LU 87007A LU 87007 A1 LU87007 A1 LU 87007A1
- Authority
- LU
- Luxembourg
- Prior art keywords
- urokinase
- pro
- unit dose
- injection
- dose
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 12
- 108010073863 saruplase Proteins 0.000 claims description 97
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 86
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 86
- 229960005356 urokinase Drugs 0.000 claims description 85
- 238000002347 injection Methods 0.000 claims description 36
- 239000007924 injection Substances 0.000 claims description 36
- 238000001802 infusion Methods 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 10
- 229960002897 heparin Drugs 0.000 claims description 10
- 229920000669 heparin Polymers 0.000 claims description 10
- 230000002195 synergetic effect Effects 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 239000003527 fibrinolytic agent Substances 0.000 claims description 4
- 230000002537 thrombolytic effect Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 229960000103 thrombolytic agent Drugs 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- 238000011260 co-administration Methods 0.000 claims description 2
- 230000003389 potentiating effect Effects 0.000 claims description 2
- 230000009089 cytolysis Effects 0.000 description 8
- 208000010125 myocardial infarction Diseases 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 6
- 102000009123 Fibrin Human genes 0.000 description 5
- 108010073385 Fibrin Proteins 0.000 description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229950003499 fibrin Drugs 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 4
- 238000002586 coronary angiography Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 3
- 239000000006 Nitroglycerin Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 229960003711 glyceryl trinitrate Drugs 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 201000010516 hypertrophic cardiomyopathy 7 Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8623823 | 1986-10-03 | ||
| GB868623823A GB8623823D0 (en) | 1986-10-03 | 1986-10-03 | Therapeutic lysis of fibrin blood clots |
| GB8628741 | 1986-12-02 | ||
| GB868628741A GB8628741D0 (en) | 1986-12-02 | 1986-12-02 | Therapeutic lysis of fibrin blood clots |
| GB8707551 | 1987-03-30 | ||
| GB878707551A GB8707551D0 (en) | 1987-03-30 | 1987-03-30 | Therapeutic lysis of fibrin blood clots |
| GB8715678 | 1987-07-03 | ||
| GB878715678A GB8715678D0 (en) | 1987-07-03 | 1987-07-03 | Therapeutic lysis of fibrin blood clots |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU87007A1 true LU87007A1 (fr) | 1988-05-03 |
Family
ID=27449820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU87007A LU87007A1 (fr) | 1986-10-03 | 1987-10-01 | Compositions pharmaceutiques a base d'urokinase |
Country Status (19)
| Country | Link |
|---|---|
| KR (1) | KR960002738B1 (https=) |
| AU (1) | AU7932587A (https=) |
| BE (1) | BE1002058A4 (https=) |
| CA (1) | CA1323300C (https=) |
| CH (1) | CH678599A5 (https=) |
| DE (1) | DE3731776A1 (https=) |
| DK (1) | DK519287A (https=) |
| FI (1) | FI874320A7 (https=) |
| FR (1) | FR2605225B1 (https=) |
| GR (1) | GR871528B (https=) |
| HU (1) | HUT47032A (https=) |
| IL (1) | IL84061A0 (https=) |
| IT (1) | IT1230114B (https=) |
| LU (1) | LU87007A1 (https=) |
| MY (1) | MY101943A (https=) |
| NL (1) | NL8702234A (https=) |
| NO (1) | NO874143L (https=) |
| PT (1) | PT85848B (https=) |
| SE (1) | SE466531B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8503097A (nl) * | 1985-11-11 | 1987-06-01 | Leuven Res & Dev Vzw | Geneesmiddel met thrombolytische werking. |
-
1987
- 1987-09-18 NL NL8702234A patent/NL8702234A/nl not_active Application Discontinuation
- 1987-09-18 HU HU874172A patent/HUT47032A/hu unknown
- 1987-09-22 DE DE19873731776 patent/DE3731776A1/de not_active Ceased
- 1987-09-28 FR FR8713486A patent/FR2605225B1/fr not_active Expired - Fee Related
- 1987-09-28 BE BE8701102A patent/BE1002058A4/fr active
- 1987-09-28 CH CH3749/87A patent/CH678599A5/de not_active IP Right Cessation
- 1987-10-01 FI FI874320A patent/FI874320A7/fi not_active IP Right Cessation
- 1987-10-01 SE SE8703788A patent/SE466531B/sv not_active IP Right Cessation
- 1987-10-01 GR GR871528A patent/GR871528B/el unknown
- 1987-10-01 CA CA000548421A patent/CA1323300C/en not_active Expired - Fee Related
- 1987-10-01 PT PT85848A patent/PT85848B/pt unknown
- 1987-10-01 NO NO874143A patent/NO874143L/no unknown
- 1987-10-01 LU LU87007A patent/LU87007A1/fr unknown
- 1987-10-01 IL IL84061A patent/IL84061A0/xx unknown
- 1987-10-02 KR KR1019870011020A patent/KR960002738B1/ko not_active Expired - Fee Related
- 1987-10-02 DK DK519287A patent/DK519287A/da not_active Application Discontinuation
- 1987-10-02 AU AU79325/87A patent/AU7932587A/en not_active Abandoned
- 1987-10-02 IT IT8748444A patent/IT1230114B/it active
- 1987-10-08 MY MYPI87002871A patent/MY101943A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA1323300C (en) | 1993-10-19 |
| NO874143D0 (no) | 1987-10-01 |
| FI874320L (fi) | 1988-04-04 |
| BE1002058A4 (fr) | 1990-06-12 |
| HUT47032A (en) | 1989-01-30 |
| FI874320A7 (fi) | 1988-04-04 |
| MY101943A (en) | 1992-02-15 |
| IL84061A0 (en) | 1988-03-31 |
| IT8748444A0 (it) | 1987-10-02 |
| GR871528B (en) | 1988-02-23 |
| IT1230114B (it) | 1991-10-07 |
| PT85848A (en) | 1987-11-01 |
| CH678599A5 (https=) | 1991-10-15 |
| DK519287A (da) | 1988-04-04 |
| KR880004821A (ko) | 1988-06-27 |
| FR2605225B1 (fr) | 1994-02-04 |
| DE3731776A1 (de) | 1988-05-05 |
| NL8702234A (nl) | 1988-05-02 |
| NO874143L (no) | 1988-04-05 |
| KR960002738B1 (ko) | 1996-02-26 |
| FR2605225A1 (fr) | 1988-04-22 |
| SE8703788L (sv) | 1988-04-04 |
| FI874320A0 (fi) | 1987-10-01 |
| AU7932587A (en) | 1988-04-14 |
| SE466531B (sv) | 1992-03-02 |
| SE8703788D0 (sv) | 1987-10-01 |
| DK519287D0 (da) | 1987-10-02 |
| PT85848B (en) | 1990-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BE1001425A4 (fr) | Utilisation de l'activateur tissulaire du plasminogene, son association avec une superoxyde-dismutase et formulation pharmaceutique contenant cette association. | |
| US5906988A (en) | Methods of treatment using ranolazine and related piperazine derivatives | |
| RU2166326C2 (ru) | Комбинация тромболитически активных белков и антикоагулянтов | |
| LU86444A1 (fr) | Nouvelle compostion d'activateur tissulaire du plasminogene | |
| JPH03503289A (ja) | 膵臓炎及び膵臓移植組織中の免疫拒絶の治療に於けるｓ‐アデノシル‐メチオニン | |
| Payseur et al. | Pulmonary alveolar proteinosis: a progressive, diffuse, fatal pulmonary disease | |
| Persson et al. | Streptokinase as an adjunct to arterial surgery | |
| JPH0283335A (ja) | 血栓溶解剤 | |
| Salvati et al. | Role of enhanced glomerular synthesis of thromboxane A2 in progressive kidney disease | |
| JPS6391327A (ja) | 有機化合物に関する改良 | |
| LU87007A1 (fr) | Compositions pharmaceutiques a base d'urokinase | |
| BE1013921A3 (fr) | Composition pharmaceutique pour traiter les maladies degeneratives. | |
| Schoebel et al. | Chronic‐intermittent urokinase therapy in patients with end‐stage coronary artery disease and refractory angina pectoris—A pilot study | |
| JPH0273022A (ja) | 組織プラスミノーゲン活性化因子を用いた薬学的製剤 | |
| JPS6150927B2 (https=) | ||
| CN1320922C (zh) | 基于用丙二烯氧合酶将脂质过氧化物酶消除的心脏保护疗法 | |
| FR2806911A1 (fr) | Utilisation de mimetiques de la sod dans le traitement d'insuffisances hepatocellulaires | |
| JP2958650B2 (ja) | 新規な血栓溶解組成物 | |
| Villota et al. | Cocaine-induced coronary thrombosis and acute myocardial infarction | |
| Stier Jr et al. | Beneficial action of beraprost sodium, a prostacyclin analog, in stroke-prone rats | |
| WO1992022202A1 (en) | Thrombolytic and perfluorochemical treatment for myocardial infraction | |
| JPH089546B2 (ja) | 抗血栓医薬組成物 | |
| Hillis | Prostaglandins and the cardiovascular system | |
| Serebruany et al. | Serial changes of the plasma prostanoids during myocardial ischemia—reperfusion in swine. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor | |
| Di Pasquale et al. | Thrombolysis plus heparin versus heparin alone in the acute phases of unstable angina: preliminary findings |